Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MNKD – MannKind Corporation

MannKind Corporation
MNKD
$5.63
Name : MannKind Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,728,805,632.00
EPSttm : 0.1
finviz dynamic chart for MNKD
MannKind Corporation
$5.63
1.92%
$0.11

Float Short %

8.79

Margin Of Safety %

-6

Put/Call OI Ratio

0.21

EPS Next Q Diff

EPS Last/This Y

0.09

EPS This/Next Y

-0.05

Price

5.74

Target Price

9.61

Analyst Recom

1

Performance Q

5.9

Relative Volume

0.49

Beta

0.75

Ticker: MNKD




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-13MNKD5.640.170.0774456
2026-01-14MNKD5.620.170.1274703
2026-01-15MNKD5.580.170.2875070
2026-01-16MNKD5.220.180.0875498
2026-01-20MNKD5.50.220.2848802
2026-01-21MNKD5.720.220.2353977
2026-01-22MNKD5.910.230.0256863
2026-01-23MNKD5.460.220.3559070
2026-01-26MNKD5.570.230.1657575
2026-01-27MNKD5.590.230.2857912
2026-01-28MNKD5.640.230.1458359
2026-01-29MNKD5.80.230.1560055
2026-01-30MNKD5.790.230.0361496
2026-02-02MNKD5.980.230.0960791
2026-02-03MNKD6.220.230.3061478
2026-02-05MNKD5.520.230.0262251
2026-02-09MNKD5.930.210.1064788
2026-02-10MNKD5.840.210.1665980
2026-02-11MNKD5.740.210.0866015
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-01-13MNKD5.65- - 0.19
2026-01-14MNKD5.61- - 0.19
2026-01-15MNKD5.58- - 0.19
2026-01-16MNKD5.22- - 0.19
2026-01-20MNKD5.50- - 0.19
2026-01-21MNKD5.72- - 0.19
2026-01-22MNKD5.90- - 0.19
2026-01-23MNKD5.46- - 0.19
2026-01-26MNKD5.57- - 0.19
2026-01-27MNKD5.59- - 0.19
2026-01-28MNKD5.65- - 0.19
2026-01-29MNKD5.80- - 0.19
2026-01-30MNKD5.79- - 0.19
2026-02-02MNKD6.00- - 0.19
2026-02-03MNKD6.22- - 0.19
2026-02-04MNKD5.78- - 0.19
2026-02-05MNKD5.52- - 0.19
2026-02-06MNKD5.78- - 0.19
2026-02-09MNKD5.93- - 0.19
2026-02-10MNKD5.84- - 0.19
2026-02-11MNKD5.74- - 0.19
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-13MNKD-6.050.858.62
2026-01-14MNKD-6.050.858.62
2026-01-15MNKD-6.050.858.62
2026-01-16MNKD-6.050.858.62
2026-01-20MNKD-5.210.598.62
2026-01-21MNKD-5.210.598.62
2026-01-22MNKD-5.210.598.62
2026-01-23MNKD-5.210.598.62
2026-01-26MNKD-5.210.588.62
2026-01-27MNKD-5.210.588.62
2026-01-28MNKD-5.210.589.15
2026-01-29MNKD-5.210.589.15
2026-01-30MNKD-5.210.589.15
2026-02-02MNKD-5.210.479.15
2026-02-03MNKD-5.210.479.15
2026-02-04MNKD-5.210.479.15
2026-02-05MNKD-5.210.479.15
2026-02-06MNKD-5.210.479.15
2026-02-09MNKD-5.21-0.389.15
2026-02-10MNKD-5.21-0.389.15
2026-02-11MNKD-5.21-0.388.79
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.07

Avg. EPS Est. Current Quarter

0.03

Avg. EPS Est. Next Quarter

0.07

Insider Transactions

-5.21

Institutional Transactions

-0.38

Beta

0.75

Average Sales Estimate Current Quarter

100

Average Sales Estimate Next Quarter

110

Fair Value

5.4

Quality Score

86

Growth Score

65

Sentiment Score

52

Actual DrawDown %

24.8

Max Drawdown 5-Year %

-57.3

Target Price

9.61

P/E

60.87

Forward P/E

67.14

PEG

2.02

P/S

5.62

P/B

P/Free Cash Flow

41.24

EPS

0.09

Average EPS Est. Cur. Y​

0.19

EPS Next Y. (Est.)

0.15

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

9.32

Relative Volume

0.49

Return on Equity vs Sector %

-93.5

Return on Equity vs Industry %

-77.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

MannKind Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 403
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
stock quote shares MNKD – MannKind Corporation Stock Price stock today
news today MNKD – MannKind Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch MNKD – MannKind Corporation yahoo finance google finance
stock history MNKD – MannKind Corporation invest stock market
stock prices MNKD premarket after hours
ticker MNKD fair value insiders trading